Retrospective Study
Copyright ©The Author(s) 2019.
World J Clin Cases. Aug 26, 2019; 7(16): 2204-2216
Published online Aug 26, 2019. doi: 10.12998/wjcc.v7.i16.2204
Table 4 Risk factors for the development of bacterial and/or fungal infections
TotalSecondary infectionn (%)χ2OR (95%CI)P-value
GenderFemale3632 (88.89)9.2635.46 (1.83, 16.31)0.002
Male13882 (59.42)
Age (yr)≥ 4510780 (74.77)10.2142.88 (1.51, 5.49)0.001
< 456734 (50.75)
HBVDNA (IU/mL)< 4.575 × 1057959 (74.68)6.2812.32 (1.20, 4.46)0.012
≥ 4.575 × 1059555 (57.89)
Stage of liver failureMiddle and late131102 (77.9)30.4599.09 (4.15, 19.89)0.000
Early4312 (27.91)
ACLF gradeACLF-14115 (36.59)18.1175.05 (2.40, 10.64)0.000
ACLF-(2, 3)13399 (74.44)
ALT (U/L)< 493.59775 (78.95)15.2733.71 (1.92, 7.17)0.000
≥ 493.57739 (50.65)
AST (U/L)<538.512092 (76.67)19.8474.78 (2.40, 9.51)0.000
≥ 538.55422 (40.74)
TBIL (µmol/mL)≥ 348.354034 (85)7.9253.83 (1.50, 9.73)0.005
< 348.3513480 (59.7)
WBC (G/L)≥ 102424 (100)7.09915.73 (2.07, 119.45)0.008
< 1015090 (60)
NE%> 708671 (82.56)20.2834.95 (2.47, 9.94)0.000
≤ 708843 (48.86)
Hospital stay (d)≥ 304840 (83.33)9.3121.45 (0.66, 3.17)0.003
< 3012674 (58.73)
ALB (g/L)≤ 33.110176 (75.25)9.8122.80 (1.47, 5.33)0.002
> 33.17338 (52.05)
PT (s)≥ 27.555848 (82.76)10.6853.64 (1.68, 7.89)0.001
< 27.5511666 (56.89)